Paying users zone. Data is covered by 
.
Get 1 month access to Regeneron Pharmaceuticals Inc. for $13.99, or
get full access to entire website for at least 3 months from $49.99.
We accept:
Regeneron Pharmaceuticals Inc. (REGN)
Analysis of Debt
Difficulty: Advanced
Total Debt (Carrying Amount)
Regeneron Pharmaceuticals Inc., Statement of Financial Position, Debt
US$ in thousands
Based on: 10-K (filing date: 2019-02-07), 10-K (filing date: 2018-02-08), 10-K (filing date: 2017-02-09), 10-K (filing date: 2016-02-11), 10-K (filing date: 2015-02-12).
| Item | Description | The company |
|---|---|---|
| Total debt (carrying amount) | Sum of the carrying values as of the balance sheet date of all debt plus capital lease obligations. | Regeneron Pharmaceuticals Inc.’s total debt increased from 2016 to 2017 and from 2017 to 2018. |
Total Debt (Fair Value)
| Dec 31, 2018 | |
|---|---|
| Selected Financial Data (US$ in thousands) | |
| Capital and facility lease obligations | |
| Convertible senior notes | |
| Total debt (fair value) | |
| Financial Ratio | |
| Debt, fair value to carrying amount ratio | |
Based on: 10-K (filing date: 2019-02-07).
Weighted-average Interest Rate on Debt
Weighted-average interest rate on debt:
| Interest Rate | Debt Amount1 | Interest Rate × Debt Amount | Weighted-average Interest Rate2 |
|---|---|---|---|
|
|
|
|
| Total | |
|
|
|
|||
Based on: 10-K (filing date: 2019-02-07).
1 US$ in thousands
2 Weighted-average interest rate = 100 × ÷ =